U.S. Markets closed

Alnylam Pharma (ALNY) Crumbles: Stock Falls by 5.2%

Zacks Equity Research

Alnylam Pharmaceuticals, Inc. (ALNY) saw a big move last session, as the company’s shares fell by over 5% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for ALNY, as the stock is now down about 23% in the past one-month time frame.

This slump shouldn’t be too much of a surprise to investors, as the company has seen 1 negative revision in the past few weeks and its current year loss consensus has widened over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.

ALNY currently has a Zacks Rank #3 (Hold) while its  Earnings ESP is 0.0%.

Some better-ranked stocks in the Med-Biomed/Generic sector include ANI Pharmaceuticals, Inc. (ANIP), Gilead Sciences Inc. (GILD) and Alkermes plc (ALKS). All these stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>






ALNYLAM PHARMACEUTICALS INC (ALNY): Free Stock Analysis Report


Zacks Investment Research